# Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020 > Briefs, arguments, decisions, and more. URL: https://www.frixlaw.com/law-library/documents/fr%3A2020-26443 ## Record - **Collection:** Federal Register - **Document type:** Notice - **Published:** December 1, 2020 - **Citation:** 85 FR 77243 ## Text DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA-508F] Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2020 AGENCY: Drug Enforcement Administration, Department of Justice. ACTION: Final order. SUMMARY: This final order establishes the final adjusted 2020 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. DATES: This order is effective December 1, 2020. FOR FURTHER INFORMATION CONTACT: Scott A. Brinks, Regulatory Drafting and Policy Support Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (571) 362-3261. SUPPLEMENTARY INFORMATION: Legal Authority Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas (APQ) for each basic class of controlled substances listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the Drug Enforcement Administration (DEA) pursuant to 28 CFR 0.100. Background DEA published the 2020 established APQ for controlled substances in schedules I and II and for the assessment of annual needs (AAN) for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine in the Federal Register on December 2, 2019. 84 FR 66014. DEA is committed to preventing and limiting diversion by enforcing laws and regulations regarding controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, while meeting the legitimate medical, scientific, and export needs of the United States. This notice stated that the Administrator would adjust, as needed, the established APQ in 2020 in accordance with 21 CFR 1303.13 and 21 CFR 1315.13. In response to the public health emergency declared by the Secretary of Health and Human Services (HHS) on January 31, 2020, DEA published the final order titled “Adjustments to Aggregate Production Quotas for Certain Schedule II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine and Pseudoephedrine for 2020” on April 10, 2020. (85 FR 20302). While the adjustments were effective immediately, all interested persons were invited to comment on or object to the adjustments on or before May 11, 2020. The 2020 proposed adjusted APQ for controlled substances in schedules I and II and AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine were subsequently published in the Federal Register on September 1, 2020, (85 FR 54414), after consideration of the criteria outlined in that notice. All interested persons were invited to comment on or object to the proposed APQs and AANs on or before October 1, 2020. Comments Received DEA received five timely comments and one untimely comment in response to the April Federal Register notice and nine comments in response to the September Federal Register notice from patients, DEA-registered entities, and non-DEA entities. The comments included appreciation of DEA's response to the public health emergency, concerns about potential drug shortages, interference with doctor-patient relationships, and comments outside the scope of this final order. Issue: Commenters expressed appreciation of DEA's flexibility in responding to the nationwide public health emergency declared by the Secretary of HHS on January 31, 2020, by adjusting APQ for select schedule II controlled substances and list I chemicals. DEA Response: DEA acknowledges the expressions of appreciation to changes in the APQ and AAN. The adjustments to select schedule II controlled substances and list I chemicals occurred after DEA consulted with HHS and determined the utilization rates for these drugs substantially increased due to the treatment regimens for ventilator patients stricken with the Coronavirus Disease of 2019 (COVID-19) compared to the previously estimated annual consumption rates. While the estimates from HHS provided a wide range in the number of patients that would require ventilation treatment due to COVID-19, DEA could, under 21 CFR 1303.13 and 1315.13, adjust the APQ and AAN for schedule II controlled substances and list I chemicals, respectively, to ensure manufacturing activities cover the upper range of the estimate could occur in a timely manner. DEA highlights factor 21 CFR 1303.13(b)(5) specifically, which allowed the Acting Administrator to increase the APQ and AAN for select controlled substances and list I chemicals to meet additional estimated medical needs as determined by HHS due to the unforeseen emergency caused by the COVID-19 pandemic. Issue: Commenters expressed general concerns that decreasing the APQ of controlled substances could lead to shortages of controlled substance medications. One DEA-registered entity submitted a comment requesting the APQ for hydrocodone (for sale) and oxycodone (for sale) be sufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, for export requirements, and for the establishment and maintenance of reserve stocks. DEA Response: DEA sets APQ in a manner to ensure that the estimated medical, scientific, research, industrial needs of the United States, lawful export requirements, and for the establishment and maintenance of reserve stocks. As discussed in both notices for adjustments, any adjustments to the APQ for controlled substances is based on factors set forth in 21 CFR 1303.13. In the event of a shortage, the CSA provides a mechanism under which DEA will, in appropriate circumstances, increase quotas to address shortages. 21 U.S.C. 826(h). Under 21 U.S.C. 826(h)(1), after receiving a request to address a shortage, DEA has 30 days to complete review of the request and determine whether adjustments are necessary to address the shortage. If adjustments are necessary, DEA is required to increase the APQ and individual production quotas to alleviate the shortage. Id. If DEA determines adjustments are not necessary, DEA is required to “provide a written response detailing the basis for the . . . determination.” Id. In addition to what Section 826(h)(1) requires, when DEA is notified of an alleged shortage, DEA will confer with the U.S. Food and Drug Administration and relevant manufacturers regarding the amount of material in physical inventory, current quota granted, and the estimated legitimate medical need, to determine whether a quota adjustment is necessary to alleviate any factually valid shortage. In accordance with 21 CFR 1303.13, DEA considered the comments for hydrocodone (for sale) and oxycodone (for sale), and the Acting Administrator determined the proposed adjusted 2020 APQs for these substances as published in the Federal Register on September 1, 2020, (85 FR 54414), are sufficient to meet the current 2020 estimated medical, scientific, research, and industrial needs of the United States, and to provide for adequate reserve stock. Issue: DEA received comments of general concerns alleging decreases to the APQ interfered with doctor-patient relationships. DEA Response: In determining the APQ, DEA considers prescriptions that have been issued. However, DEA does not interfere with doctor-patient relationships. Doctors authorized to dispense controlled substances are responsible for adhering to the laws and regulations set forth under the CSA, which requires doctors to only write prescriptions for a legitimate medical need. DEA is responsible for enforcing controlled substance laws and regulations, and is committed to ensuring an adequate and uninterrupted supply of controlled substances in order to meet the demand of legitimate medical, scientific, and export needs of the United States. Untimely Comment Issue: The DEA received one comment from a DEA-registered entity for previously established value of the 2020 AAN for pseudoephedrine (for conversion), requesting an increase because the established AAN is not adequate to cover the commenter's new projected need for 2020. DEA Response: The comment was received in between the comment periods for the two notices of adjustment. Even though the comment was outside the comment period that ended on May 11, 2020, DEA considered this comment as part of the second comment period ending on October 1, 2020, when setting the final 2020 AAN. Out of Scope Comments: DEA received comments on issues outside the scope of this final order. The comments were general in nature and raised issues of specific medical illnesses, medical treatments, and medication costs, and therefore, are outside of the scope of this Final Order for 2020 and do not impact the original analysis involved in finalizing the 2020 APQ. Analysis for Final Adjusted 2020 Aggregate Production Quotas and Assessment of Annual Needs In determining the final adjusted 2020 APQ and AAN, DEA has considered the above comments relevant to this Final Order for calendar year 2020, along with the factors set forth in 21 CFR 1303.13 and 21 CFR 1315.13, in accordance with 21 U.S.C. 826(a). DEA has also considered other relevant factors, including the 2019 year-end inventories, initial 2020 manufacturing and import quotas, 2020 export requirements, actual and projected 2020 sales, research and product development requirements, additional applications received, and the extent of any diversion of the controlled substance in the class. Based on all of the above, the Acting Administrator is adjusting the 2020 APQ for the following: Increases for Amphetamine (for sale) and Methamphetamine, based on the data received since the publication of the 2020 proposed adjustment for APQ and AAN in the Federal Register on September 1, 2020 (85 FR 54414); increases for Crotonyl Fentanyl, Ethylone, and Isotonitazene due to the publication of their schedule I temporary controlled status; and increases for Etonitazene due to additional manufacturers entering the reference standard market. This final order reflects those adjustments. Pursuant to the above, the Acting Administrator hereby finalizes the 2020 APQ for the following schedule I and II controlled substances and the 2020 AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows: Basic class Final revised 2020 quotas (g) Temporarily Scheduled Substances Crotonyl fentanyl 25 Ethylone 25 Isotonitazene 25 Schedule I 1-[1-(2-Thienyl)cyclohexyl]pyrrolidine 20 1-(1-Phenylcyclohexyl)pyrrolidine 15 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine 10 1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201) 30 1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694) 30 1-Benzylpiperazine 25 1-Methyl-4-phenyl-4-propionoxypiperidine 10 1-[1-(2-Thienyl)cyclohexyl]piperidine 15 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E) 30 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D) 30 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N) 30 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P) 30 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H) 100 2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36) 30 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C) 30 2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82) 25 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I) 30 2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5) 30 2,5-Dimethoxy-4-ethylamphetamine (DOET) 25 2,5-Dimethoxy-4-(n)-propylthiophenethylamine 25 2,5-Dimethoxyamphetamine (DMA) 25 2-(4-Ethylthio-2,5-dimethoxyphenyl)ethanamine (2C-T-2) 30 2-(4-(Isopropylthio)-2,5-dimethoxyphenyl)ethanamine (2C-T-4) 30 3,4,5-Trimethoxyamphetamine 30 3,4-Methylenedioxyamphetamine (MDA) 55 3,4-Methylenedioxymethamphetamine (MDMA) 50 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) 40 3,4-Methylenedioxy-N-methylcathinone (methylone) 40 3,4-Methylenedioxypyrovalerone (MDPV) 35 3-Fluoro-N-methylcathinone (3-FMC) 25 3-Methylfentanyl 30 3-Methylthiofentanyl 30 4-Bromo-2,5-dimethoxyamphetamine (DOB) 30 4-Bromo-2,5-dimethoxyphenethylamine (2-CB) 25 4-Chloro-alpha-pyrrolidinovalerophenone (4-chloro-alpha-PVP) 25 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1 H-indazole-3-carboximide (4CN-Cumyl-Butinaca) 25 4-Fluoroisobutyryl fentanyl 30 4-Fluoro-N-methylcathinone (4-FMC; Flephedrone) 25 4-Methyl-N-ethylcathinone (4-MEC) 25 4-Methoxyamphetamine 150 4-Methyl-2,5-dimethoxyamphetamine (DOM) 25 4-Methylaminorex 25 4-Methyl-N-methylcathinone (mephedrone) 45 4-Methyl-alpha-ethylaminopentiophenone (4-MEAP) 25 4-Methyl-alpha-pyrrolidinohexiophenone (MPHP) 25 4-Methyl-alpha-pyrrolidinopropiophenone (4-MePPP) 25 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol 50 5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol (cannabicyclohexanol or CP-47,497 C8-homolog) 40 5F-CUMYL-PINACA 25 5F-EDMB-PINACA 25 5F-MDMB-PICA 25 5F-AB-PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide 25 5F-CUMYL-P7AICA; (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboximide) 25 5F-ADB; 5F-MDMB-PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) 30 5F-AMB (methyl 2-(1-(5-fluoropentyl)-1 H -indazole-3-carboxamido)-3-methylbutanoate) 30 5F-APINACA; 5F-AKB48 ( N -(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide) 30 5-Fluoro-PB-22; 5F-PB-22 20 5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1 H- indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone 25 5-Methoxy-3,4-methylenedioxyamphetamine 25 5-Methoxy-N,N-diisopropyltryptamine 25 5-Methoxy-N,N-dimethyltryptamine 25 AB-CHMINACA 30 AB-FUBINACA 50 AB-PINACA 30 ADB-FUBINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) 30 Acetorphine 25 Acetyl Fentanyl 100 Acetyl-alpha-methylfentanyl 30 Acetyldihydrocodeine 30 Acetylmethadol 25 Acryl Fentanyl 25 ADB-PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) 50 AH-7921 30 Allylprodine 25 Alphacetylmethadol 25 Alpha - Ethyltryptamine 25 Alphameprodine 25 Alphamethadol 25 Alphaprodine 25 Alpha-Methylfentanyl 30 Alpha-Methylthiofentanyl 30 Alpha-Methyltryptamine (AMT) 25 Alpha-Pyrrolidinobutiophenone (α-PBP) 25 Alpha-Pyrrolidinoheptaphenone (PV8) 25 Alpha - Pyrrolidinohexanophenone (α-PHP) 25 Alpha-Pyrrolidinopentiophenone (α-PVP) 25 Aminorex 25 Anileridine 20 APINACA, AKB48 ( N -(1-adamantyl)-1-pentyl-1 H -indazole-3-carboxamide) 25 Benzethidine 25 Benzylmorphine 30 Betacetylmethadol 25 Beta-Hydroxy-3-methylfentanyl 30 Beta-Hydroxyfentanyl 30 Beta-Hydroxythiofentanyl 30 Betameprodine 25 Betamethadol 4 Betaprodine 25 Bufotenine 15 Butylone 25 Butyryl fentanyl 30 Cathinone 40 Clonitazene 25 Codeine methylbromide 30 Codeine-N-oxide 192 Cyclopentyl Fentanyl 30 Cyclopropyl Fentanyl 20 Cyprenorphine 25 Desomorphine 25 Dextromoramide 25 Diampromide 20 Diethylthiambutene 20 Diethyltryptamine 25 Difenoxin 9,200 Dihydromorphine 753,500 Dimenoxadol 25 Dimepheptanol 25 Dimethylthiambutene 20 Dimethyltryptamine 50 Dioxaphetyl butyrate 25 Dipipanone 25 Drotebanol 25 Ethylmethylthiambutene 25 Etonitazene 25 Etorphine 30 Etoxeridine 25 Fenethylline 30 Fentanyl related substances 600 FUB-144 25 FUB-AKB48 25 FUB-AMB, MMB-Fubinaca, AMB-Fubinaca 25 Furanyl fentanyl 30 Furethidine 25 Gamma Hydroxybutyric Acid 29,417,000 Heroin 45 Hydromorphinol 40 Hydroxypethidine 25 Ibogaine 30 Isobutyryl Fentanyl 25 JWH-018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole) 35 JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) 45 JWH-073 (1-Butyl-3-(1-naphthoyl)indole) 45 JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl)indole) 30 JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) 30 JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) 35 JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) 30 JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) 30 JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) 30 Ketobemidone 30 Levomoramide 25 Levophenacylmorphan 25 Lysergic acid diethylamide (LSD) 40 MAB-CHMINACA; ADB-CHMINACA ( N -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1 H -indazole-3-carboxamide) 30 MDMB-CHMICA; MMB-CHMINACA (methyl 2-(1-(cyclohexylmethyl)-1 H -indole-3-carboxamido)-3,3-dimethylbutanoate) 30 MDMB-FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) 30 MMB-CHMICA (AMB-CHMICA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate 25 Marihuana 3,200,000 Mecloqualone 30 Mescaline 25 Methaqualone 60 Methcathinone 25 Methoxyacetyl fentanyl 30 Methyldesorphine 5 Methyldihydromorphine 25 Morpheridine 25 Morphine methylbromide 5 Morphine methylsulfonate 5 Morphine-N-oxide 150 MT-45 30 Myrophine 25 NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate 25 N,N-Dimethylamphetamine 25 Naphyrone 25 N-Ethyl-1-phenylcyclohexylamine 25 N-Ethyl-3-piperidyl benzilate 10 N-Ethylamphetamine 24 N - Ethylhexedrone 25 N - Ethylpentylone, ephylone 30 N-Hydroxy-3,4-methylenedioxyamphetamine 24 N-Methyl-3-Piperidyl Benzilate 30 Nicocodeine 25 Nicomorphine 25 Noracymethadol 25 Norlevorphanol 55 Normethadone 25 Normorphine 40 Norpipanone 25 Ocfentanil 25 Ortho-fluorofentanyl, 2-fluorofentanyl 30 Para-chloroisobutyryl fentanyl 30 Para-fluorofentanyl 25 Para-fluorobutyryl fentanyl 25 Para-methoxybutyryl fentanyl 30 Parahexyl 5 PB-22; QUPIC 20 Pentedrone 25 Pentylone 25 Phenadoxone 25 Phenampromide 25 Phenomorphan 25 Phenoperidine 25 Pholcodine 5 Piritramide 25 Proheptazine 25 Properidine 25 Propiram 25 Psilocybin 30 Psilocyn 50 Racemoramide 25 SR-18 and RCS-8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) 45 SR-19 and RCS-4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole) 30 Tetrahydrocannabinols 384,460 Tetrahydrofuranyl fentanyl 15 Thebacon 25 Thiafentanil 25 Thiofentanyl 25 THJ-2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone) 30 Tilidine 25 Trimeperidine 25 UR-144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone 25 U-47700 30 Valeryl fentanyl 25 Schedule II 1-Phenylcyclohexylamine 15 1-Piperidinocyclohexanecarbonitrile 25 4-Anilino-N-phenethyl-4-piperidine (ANPP) 934,956 Alfentanil 3,260 Alphaprodine 25 Amobarbital 20,100 Amphetamine (for conversion) 14,137,578 Amphetamine (for sale) 44,330,000 Bezitramide 25 Carfentanil 20 Cocaine 73,090 Codeine (for conversion) 3,225,000 Codeine (for sale) 35,341,292 Dextropropoxyphene 35 Dihydrocodeine 156,713 Dihydroetorphine 25 Diphenoxylate (for conversion) 14,100 Diphenoxylate (for sale) 770,800 Ecgonine 78,439 Ethylmorphine 30 Etorphine hydrochloride 32 Fentanyl 934,956 Glutethimide 25 Hydrocodone (for conversion) 1,250 Hydrocodone (for sale) 33,997,285 Hydromorphone 3,512,651 Isomethadone 30 Levo-alphacetylmethadol (LAAM) 25 Levomethorphan 30 Levorphanol 31,730 Lisdexamfetamine 21,000,000 Meperidine 1,119,862 Meperidine Intermediate-A 30 Meperidine Intermediate-B 30 Meperidine Intermediate-C 30 Metazocine 15 Methadone (for sale) 25,619,700 Methadone Intermediate 27,673,600 Methamphetamine 1,224,109 [678,878 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 505,231 grams for methamphetamine mostly for conversion to a schedule III product; and 40,000 grams for methamphetamine (for sale).] Methylphenidate 57,438,334 Metopon 25 Moramide-intermediate 25 Morphine (for conversion) 3,376,696 Morphine (for sale) 33,756,703 Nabilone 62,000 Norfentanyl 25 Noroxymorphone (for conversion) 22,044,741 Noroxymorphone (for sale) 376,000 Opium (powder) 250,000 Opium (tincture) 530,837 Oripavine 33,010,750 Oxycodone (for conversion) 725,998 Oxycodone (for sale) 65,667,554 Oxymorphone (for conversion) 28,204,371 Oxymorphone (for sale) 658,515 Pentobarbital 25,850,000 Phenazocine 25 Phencyclidine 35 Phenmetrazine 25 Phenylacetone 40 Piminodine 25 Racemethorphan 5 Racemorphan 5 Remifentanil 3,000 Secobarbital 172,100 Sufentanil 4,000 Tapentadol 13,447,541 Thebaine 59,284,070 List I Chemicals Ephedrine (for conversion) 100 Ephedrine (for sale) 4,756,000 Phenylpropanolamine (for conversion) 14,100,000 Phenylpropanolamine (for sale) 16,590,000 Pseudoephedrine (for conversion) 1,000 Pseudoephedrine (for sale) 200,382,900 The Acting Administrator further proposes that APQ for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. Timothy J. Shea, Acting Administrator. [FR Doc. 2020-26443 Filed 11-30-20; 8:45 am] BILLING CODE 4410-09-P --- Source: Frix Law Library, https://www.frixlaw.com/law-library/documents/fr%3A2020-26443. Public record. Not legal advice.